about
Biomarkers Associated with the Outcome of Traumatic Brain Injury Patients.Sustained high serum caspase-3 concentrations and mortality in septic patients.Association between serum levels of caspase-cleaved cytokeratin-18 and early mortality in patients with severe spontaneous intracerebral hemorrhage.High serum levels of caspase-cleaved cytokeratin-18 are associated with malignant middle cerebral artery infarction patient mortality.Low Serum Melatonin Levels Prior to Liver Transplantation in Patients with Hepatocellular Carcinoma are Associated with Lower Survival after Liver TransplantationSerum melatonin levels are associated with mortality in patients with malignant middle cerebral artery infarction.Serum total antioxidant capacity prior to liver transplantation for hepatocellular carcinoma is associated with 1-year liver transplantation survivalTraumatic Brain Injury Patients Mortality and Serum Total Antioxidant CapacityNon-Survivor Ischemic Stroke Patients Maintain High Serum Caspase-Cleaved Cytokeratin-18 LevelsHigh Serum DNA and RNA Oxidative Damage in Non-surviving Patients with Spontaneous Intracerebral HemorrhageNon-survivor patients with malignant middle cerebral artery infarction showed persistently high serum malondialdehyde levelsHigh Serum Caspase-Cleaved Cytokeratin-18 Levels and Mortality of Traumatic Brain Injury PatientsMaintained high sustained serum malondialdehyde levels after severe brain trauma injury in non-survivor patientsHigh serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patientsSerum Caspase-3 Levels and Early Mortality of Patients with Malignant Middle Cerebral Artery InfarctionAssociation Between DNA and RNA Oxidative Damage and Mortality of Patients with Traumatic Brain InjuryHigh Serum Levels of Caspase-3 and Early Mortality in Patients with Severe Spontaneous Intracerebral Hemorrhage
P50
Q47103281-7A3417AD-D152-4BB4-B1A7-43E7F82A5124Q48337469-C6CBDD58-D605-4088-BABE-FDF43C9743EDQ52585124-03B0DF4B-EF3F-4826-B6A1-ECC603B60BB1Q52638531-C4148C2B-C9A1-4101-BDAA-17469423C5CEQ64072483-E857D1E9-5850-4CC9-9FD9-7FE06814C85EQ64997545-130B8356-C134-4EEC-9E86-E88543CADF80Q89133461-503CAFAE-EC49-41AE-9E7D-D6003C969B41Q89834702-CE09E45C-C59B-4D1D-A445-4BCF876DCBC3Q89975466-545366F5-66F4-4AC7-8C1D-1CB862EBA363Q90622779-8B1B7BE8-8977-4453-B854-E4AFD6DF5914Q90777282-EF28C907-3EFF-4E1C-A8DF-5A3CE2897375Q90972855-13C00856-0D9C-461A-90E8-99E1ADCFDE43Q91651893-FF4554FE-BDF0-479C-9EEF-D32EB7E24228Q91996509-7C6E7B01-3E98-46C5-B957-D0F4AD69748BQ92210144-3D10A1CA-ABF8-4CD5-A267-0EF6DCDCE1AFQ92440332-EA3E7ABA-9D59-4036-B191-AE0FF62916E8Q96232561-8589226C-A31B-4024-A9C2-62D6B62DE63A
P50
description
researcher
@en
wetenschapper
@nl
name
Leonardo Lorente
@en
Leonardo Lorente
@nl
type
label
Leonardo Lorente
@en
Leonardo Lorente
@nl
prefLabel
Leonardo Lorente
@en
Leonardo Lorente
@nl
P31
P496
0000-0003-4902-4065